|
|
|
Caredx Inc (NASDAQ: CDNA) |
|
|
|
| |
Caredx Inc Outlook |
On January 13 2025 the Caredx Inc provided following guidance
nnCareDx Inc. Projects Impressive Financial Growth for Q4 and Full Year 2024nn
nnJanuary 13, 2025 – Brisbane, Californiann – CareDx, Inc. (Nasdaq: CDNA), a leading company in transplant diagnostics, has released preliminary unaudited financial results for the fourth quarter and the entire year ending December 31, 2024. The figures indicate a robust upward trend in revenue, affirming the company's strong market position.
For the fourth quarter of 2024, CareDx anticipates revenues between $85 million and $86 million, reflecting an impressive year-over-year growth of approximately 30%. This positive trajectory underscores the company's continued commitment to advancing transplant medicine.
Moreover, the anticipated revenue from testing services is expected to fall between $62.5 million and $63.5 million, signifying a significant increase of around 35% compared to the previous year. This growth in testing services revenue showcases CareDx's effectiveness in meeting the rising demand for specialized transplant diagnostics and personalized medicine solutions.
Overall, these preliminary results reinforce CareDx's role as a critical player in the transplant healthcare sector and reflect the company’s ongoing efforts to enhance its service offerings and elevate patient outcomes through innovative diagnostic solutions.,
|
On October 15 2024 the Caredx Inc provided following guidance
nnCareDx Inc. Preliminary Financial Estimates for Q3 2024nn
CareDx, Inc. (Nasdaq: CDNA), a prominent leader in precision medicine dedicated to enhancing the lives of transplant patients and their caregivers, has released its preliminary financial results for the third quarter of 2024, which ended on September 30. The figures indicate a strong performance, with projected revenue anticipated to fall within the range of $82 million to $83 million.
nnQ3 2024 Revenue Forecastnn
The company’s revenue estimates reflect robust activity and growth within its market segment, thanks to CareDx's commitment to delivering innovative healthcare solutions that cater specifically to the needs of transplant patients. As CareDx continues to expand its reach and enhance its offerings, the anticipated revenue range signals promising momentum for the company as it heads into the final quarter of the fiscal year.
nnConclusionnn
Overall, the preliminary figures for the third quarter highlight CareDx's ongoing success in driving its innovative healthcare solutions forward, reinforcing its position as a key player in the transplant healthcare industry. Stakeholders can look forward to more comprehensive results and insights as the company prepares to finalize its performance report for the quarter.,
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
